



IFW

Atty. Docket No.: 3652/2004

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Larche, et al.
Serial No.: 10/809,689
Filed: March 25, 2004
Entitled: Methods and Compositions for
Desensitisation


Examiner: Not Yet Assigned
Group Art Unit: 1644
Conf. No.: 7876

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Nancy Arsenault

Name of Person Mailing Paper


Signature of Person Mailing Paper

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Enclosed for filing in the above-identified patent application, please find the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449;
3. Copies of Cited References 1-20; and
4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any fees to Deposit Account No. 16-0085, Reference 3652/2004. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: 9/20/04


Name: Matthew Beaudet

Registration No.: 50,649


Customer No.: 29933

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100



Atty. Docket No.: 3652/2004

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Larche, et al.
Serial No.: 10/809,689
Filed: March 25, 2004
Entitled: Methods and Compositions for
Desensitisation

Examiner: Not Yet Assigned
Group Art Unit: 1644
Conf. No.: 7876

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Nancy Arsenault

Name of Person Mailing Paper

Signature of Person Mailing Paper

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A listing of the cited documents 1-20 are enclosed. References 21-29 listed on the attached Form PTO-1449 were submitted to the United States Patent and Trademark Office in the parent application, U.S. Serial No. 09/610,134 filed June 5, 2000. Therefore, no copies of these references are enclosed.

Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Date:

9/20/04

Respectfully submitted,

Name: Matthew Beaudet

Registration No.: 58,649


Customer No.: 29933

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613


Tel: 617-239-0100



U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT				Attorney Docket No. 3652/2004		Serial No. 10/809,689	
				Applicant(s): Larche, et al.			
				Filing Date: March 25, 2004		Group: 1644	
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	1.	6,025,162	Feb. 15, 2000	Rogers, et al.	435	69.3	
	2.	6,019,972	Feb. 1, 2000	Gefter, et al.	424	185.1	
	3.	6,180,368	Jan. 30, 2001	Singh, et al.	435	69.3	
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation
							YES NO
	4.	WO 99/34826	15 July 1999	PCT	A61K	39/35	
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
	5.	Briner, et al.; "Peripheral T-cell tolerance induced in naïve and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I"; (1993); <u>Proc. Natl. Acad. Sci. USA</u> ; 90: 7608-7612.					
	6.	Morgenstern, et al.; "Amino acid sequence of Fel dI, the major allergen of the domestic cat: Protein sequence analysis and cDNA cloning"; (1991); <u>Proc. Natl. Acad. Sci. USA</u> ; 88: 9690-9694.					
	7.	Oldfield, et al.; "Attenuation of Bronchial and Cutaneous Allergic Late Phase Responses by Allergen-Derived Peptides" (1999) <u>Immunology</u> ; 98: Suppl. 1: 40 (Abs. 12.16).					
	8.	Bacchetta, et al.; "High Levels of Interleukin 10 Production In Vivo Are Associated with Tolerance in SCID Patients Transplanted with HLA Mismatched Hematopoietic Stem Cells"; (1994); <u>J. Exp. Med.</u> ; 179: 493-502.					
	9.	Muller, et al.; "Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom"; (1998); <u>J. Allergy Clin. Immunol.</u> ; 101: 747-754.					
	10.	Blazar, et al.; "Interleukin-10 Dose-Dependent Regulation of CD4+ and CD8+ T Cell-Mediated Graft-Versus-Hose Disease"; (1998); <u>Transplantation</u> ; 66: 1220-1229.					
	11.	Perrin, et al.; "Mechanism of Interleukin-10 Inhibition of T-Helper Cell Activation by Superantigen at the Level of the Cell Cycle"; (1999); <u>Blood</u> ; 93(1): 208-216.					
	12.	Akdis, et al. "Role of Interleukin 10 in Specific Immunotherapy"; (1998); <u>J. Clin. Invest.</u> ; 102(1): 98-106.					
EXAMINER					DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							
**Copies of references not provided at the time of this submission.							



USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT				Attorney Docket No. 3654/2004		Serial No. 10/809,689	
				Applicant(s): Larche et al.			
				Filing Date: March 25, 2004		Group: 1644	
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation
							YES NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
	13.	Cobbold and Waldmann; "Infectious tolerance"; (1998); <u>Transplantation</u> ; 10: 518-524.					
	14.	Hoyne et al; "Inhibition of T-cell responses by feeding peptides containing major and cryptic epitopes: studies with the Der p I allergen"; (1994); <u>Immunology</u> ; 83: 190-195.					
	15.	Lamb et al; "Induction of Tolerance in Influenza Virus-Immune T Lymphocyte Clones with Synthetic Peptides of Influenza Hemagglutinin"; (1983); <u>J. Exp. Med.</u> ; 157: 1434-1447.					
	16.	Metzler and Wraith; "Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity"; (1993); <u>Int. Immunol.</u> ; 5: 1159-1165.					
	17.	Norman et al; "Treatment of Cat Allergy with T-cell Reactive Peptides"; (1996); <u>Am. J. Respir. Crit. Care Med.</u> ; 154: 1623-1628					
	18.	van Neerven et al; "Characterization of Cat Dander-Specific T Lymphocytes from Atopic Patients"; (1994); <u>J. Immunol.</u> ; 152: 4203-4210.					
	19.	van't Hof et al; "Epitope mapping of the cat (<i>Felis domesticus</i>) major allergen Fel d I by overlapping synthetic peptides and monoclonal antibodies against native and denatured Fel d I"; (1993) <u>Allergy</u> ; 48: 255-263.					
	20.	Mark et al; "Human T and B cell immune responses to Fel d 1 in cat-allergic and not-cat-allergic subjects"; (1996); <u>Clin Exp Allergy</u> ; 26(11): 1316-1328.					
EXAMINER					DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.							



USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT				Attorney Docket No. 3654/2004		Serial No. 10/809,689	
Applicant(s): Larche et al.				Filing Date: March 25, 2004		Group: 1644	

U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation	
							YES	NO
	21.	97/33910	18.09.97	WO	C07K	14/435		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
	22.	Milligen et al.; "IgE epitopes on the cat (<i>Felis domesticus</i>) major allergen Fel d 1: A study with overlapping synthetic peptides"; <u>J. Allergy Clin. Immunol.</u> ; 93(1): 34-.
	23.	Creticos, J. Herbert, et al.; "Efficacy of Allervax Ragweed peptides in the Treatment of Ragweed-Induced Allergy"; <u>J. Allergy Clin. Immunol.</u> , (1998); 99: S401, Abstract 1631.
	24.	Haselden, M., et al.; "Asthma Provoked by T Cell Epitopes; A Novel Method of Studying IgE-Independent Isolated Late Asthmatic Reactions"; <u>Clinical & Experimental Allergy</u> , (1997); 27, 1360; Abstract 11.
	25.	Haselden, M., et al., "Asthma Provoked by T-Cell Peptide Epitopes"; <u>J. Allergy Clin. Immunol.</u> ; (1998); 101, Abstract 604.
	26.	Haselden, M. et al.; "Intramolecular Variation in Cytokine Production Profiles in Allergic Asthma: A comparison of Allergen Peptide-Specific Responses in Defined Clinical Groups"; <u>J. Allergy Clin. Immunol.</u> ; (1999); 103; S230; Abstract 886.
	27.	Cookson, et al., "Alchemy for Asthma," <u>Nature Medicine Vaccine Supplement</u> ; (1998); 4: 550-551.
	28.	Hoyne, G., et al.; "Regulation of House dust mite responses by intranasally administered peptide: transient activation of CD4 ⁺ T cells precedes the development of tolerance in vivo"; <u>International Immunology</u> ; (1996). 8(3):335-342.
	29.	Wallner, B.P., et al.; "Immunotherapy with T-cell-reactive peptides derived from allergens"; (1994). <u>Allergy</u> ; 49: 302-308.

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.